Drug Therapy Protocols: Methoxyflurane

<table>
<thead>
<tr>
<th>Policy code</th>
<th>DTP_METH_0119</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>January, 2019</td>
</tr>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to methoxyflurane administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to all Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td>Health care setting</td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td>Population</td>
<td>Applies to all ages unless specifically mentioned.</td>
</tr>
<tr>
<td>Source of funding</td>
<td>Internal – 100%</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>January, 2022</td>
</tr>
</tbody>
</table>

While effort has been made to contact all copyright owners this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au
Drug class
Analgesic (at low doses)

Pharmacology
Methoxyflurane is volatile, self-administered inhalation analgesic indicated for short-term pain relief. Methoxyflurane is more susceptible to metabolism than other halogenated ethers and has a greater propensity to diffuse into fatty tissue.[1-3]

Metabolism
By the liver and excreted mainly by the lungs.[3]

Indications
- Pain

Contraindications
- Allergy and/or Adverse Drug Reaction
- Patients < 1 year
- History of significant liver or renal disease
- History of malignant hyperthermia

Precautions
- ALOC
- Intoxicated or drug affected patients

Side effects
- ALOC
- Cough
- Renal/hepatic failure (following repeated high dose exposure)

Presentation
- Bottle, 3 mL methoxyflurane

Onset (INH) | Duration (INH) | Half-life
--- | --- | ---
1–3 minutes | 5–10 minutes | Not available
**Special notes**

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the QAS Clinical Consult and Advice Line.

- Experimental and clinical use of methoxyflurane in the low dose used for analgesia does not carry any particular risk of causing renal dysfunction or damage.[3]

- The manufacturer recommends the use by children only when they self monitor pain and self-administer methoxyflurane with the inhaler. Poor administration will lead to ineffective analgesia.

- Deep sedation has been identified with methoxyflurane administration in patients < 5 years.[1,4]

- At no time should unconsciousness be deliberately induced using methoxyflurane.

- At no time should a patient self-administering methoxyflurane be left unattended.

- The lowest dose of methoxyflurane to provide analgesia should be used.[1]

- If the patient prefers simultaneous inhalation through both nose and mouth, the inhaler may be connected into a standard anaesthetic face mask prior to administration.[2]

**Special notes (cont.)**

- The total weekly dose should not exceed 15 mL with administration on consecutive days not recommended.[4]

- To reduce the risk of occupational exposure to methoxyflurane, officers are to ensure the following:
  - Only one dose of 3 mL should be administered per patient whilst in the ambulance vehicle.
  - No single officer should administer more than two doses of methoxyflurane in the ambulance vehicle per shift.
  - Where possible, ambulance vehicles are to adequately ventilated.

**Schedule**

- S4 (Restricted drugs).

**Routes of administration**

**Inhalation (INH)**

**Special notes**

- FR AT P ACP1 ACP2 CCP

**Adult dosages**

<table>
<thead>
<tr>
<th>Pain</th>
<th>INH</th>
<th>3 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>FR AT P ACP1 ACP2 CCP</td>
<td>INH</td>
<td>3 mL</td>
</tr>
</tbody>
</table>

Repeated once after 20 minutes.
Total maximum dose 6 mL.

**Paediatric dosages**

<table>
<thead>
<tr>
<th>Pain</th>
<th>INH</th>
<th>≥ 1 year – 3 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>FR AT P ACP1 ACP2 CCP</td>
<td>INH</td>
<td>≥ 1 year – 3 mL</td>
</tr>
</tbody>
</table>

Single dose only.
Methoxyflurane Preparation / Administration Instruction

1. Tilt the PENTHROX® inhaler to a 45° angle and pour the contents of one 3 mL bottle into the base whilst rotating.

2. Instruct the patient to inhale and exhale gently through the mouthpiece.

3. If stronger analgesia is required, the patient may be instructed to temporarily cover the dilution hole with their own finger to increase concentration.